GSK Hep B Drug Shows 19% Cure Rate
GSK's bepirovirsen shows promise in hepatitis B trial with 19% functional cure rate, potentially impacting treatment options. This development may affect GSK's stock and the broader pharmaceutical sector.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.